« Return to News | Drug Sponsors

Valeant Pharmaceuticals to acquire Natur Produkt in Russia

Monday, March 26, 2012 10:58 AM

Valeant Pharmaceuticals International has signed a $180 million agreement to acquire Natur Produkt International, a specialty pharmaceutical company in St. Petersburg, Russia.

Natur Produkt will have the potential to receive an additional $5 million in future milestones. The acquisition will give Valeant the Russian company’s over-the-counter brands AntiGrippin, a cough and cold remedy, Anti Angin, Sage and Eucaplyptus, sore throat remedies, and several more.

"Not only is the OTC market very attractive in Russia due to the self-pay element, but it is also one of the fastest growth components of the Russian healthcare system,” stated J. Michael Pearson, chairman and CEO, Valeant. “The addition of this high-growth operation… will bring our pro forma revenues in Russia to approximately $175 million by the end of 2012."

The transaction is expected to close by mid-year 2012, subject to certain closing adjustments and regulatory approvals, and is expected to be immediately accretive.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.